Literature DB >> 3316493

Acetylcholine and affective disorder.

S S Leong1, W A Brown.   

Abstract

We reviewed the evidence for involvement of central cholinergic neurons in affective disorder. Cholinomimetics inhibit speech, thought, and activity in most subjects, decrease manic symptoms and, in some affective disorder patients, produce depressive symptoms. Cholinomimetics also cause ACTH and cortisol secretion and decrease latency to REM sleep. It is unclear whether cholinomimetics are specifically "antimanic" or "depressogenic" or whether their fundamental effect is nonspecific behavioral inhibition; whether the observed effects of cholinomimetics are mediated largely through cholinergic pathways, are secondary to changes in other neurotransmitters or are part of a nonspecific stress response. The suggestion that anticholinergic agents have mood elevating properties has not yet been subjected to controlled investigation. Although the proposal that affective disorders involve cholinergic neurons has received some support from clinical investigation further research is required to substantiate the intriguing observations to date and to clarify the physiologic and psychologic processes mediating them.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3316493     DOI: 10.1007/BF01253604

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  56 in total

1.  Psychiatric sequelae of chronic exposure to organophosphorus insecticides.

Authors:  S GERSHON; F H SHAW
Journal:  Lancet       Date:  1961-06-24       Impact factor: 79.321

2.  Cholinergic reversal of manic symptoms.

Authors:  B J Carroll; A Frazer; A Schless; J Mendels
Journal:  Lancet       Date:  1973-02-24       Impact factor: 79.321

3.  True and pseudo cholinesterases in depression.

Authors:  R J Mathew; B T Ho; M M Khan; C Perales; M L Weinman; J L Claghorn
Journal:  Am J Psychiatry       Date:  1982-01       Impact factor: 18.112

4.  The interaction of trazodone with rat brain muscarinic cholinoceptors.

Authors:  D K Hyslop; D P Taylor
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

5.  Development and use of pharmacological probes of the CNS in man: evidence of cholinergic abnormality in primary affective illness.

Authors:  N Sitaram; J C Gillin
Journal:  Biol Psychiatry       Date:  1980-12       Impact factor: 13.382

6.  Physostigmine: effects on cognition and affect in normal subjects.

Authors:  K L Davis; L E Hollister; J Overall; A Johnson; K Train
Journal:  Psychopharmacology (Berl)       Date:  1976-12-21       Impact factor: 4.530

7.  Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain.

Authors:  E El-Fakahany; E Richelson
Journal:  Br J Pharmacol       Date:  1983-01       Impact factor: 8.739

8.  Acetylcholinesterase activity in CSF in schizophrenia, depression, Alzheimer's disease and normals.

Authors:  S I Deutsch; R C Mohs; M I Levy; A B Rothpearl; D Stockton; T Horvath; A Coco; K L Davis
Journal:  Biol Psychiatry       Date:  1983-12       Impact factor: 13.382

9.  Physostigmine induction of depressive symptomatology in normal human subjects.

Authors:  S C Risch; R M Cohen; D S Janowsky; N H Kalin; N Sitaram; J C Gillin; D L Murphy
Journal:  Psychiatry Res       Date:  1981-02       Impact factor: 3.222

10.  Clinical notes on the possible anticholinergic reversal of depressive syndromes.

Authors:  G Ungvári; I Karczag; J Gerevich; B Pethö
Journal:  Pharmacopsychiatria       Date:  1981-03
View more
  3 in total

Review 1.  Additive effects, but no synergistic interaction of stressful life-events and genetic loading in affective disorders.

Authors:  J Fritze; B Schneider; K Maurer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 2.  Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents.

Authors:  T Burt
Journal:  Curr Psychiatry Rep       Date:  2000-12       Impact factor: 5.285

3.  A randomized, 4-week double-blind placebo control study on the efficacy of donepezil augmentation of lithium for treatment of acute mania.

Authors:  Jing Chen; Zheng Lu; Mingyuan Zhang; Jie Zhang; Xiaodong Ni; Xuefeng Jiang; Heding Xu; Anisha Heeramun-Aubeeluck; Qiaoyan Hu; Hua Jin; John M Davis
Journal:  Neuropsychiatr Dis Treat       Date:  2013-06-17       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.